Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
Silica is a proven and highly effective anti-caking agent that has been used for decades
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Company receives acceptability, in principle, for ZyVac TCV making it eligible for purchase by United Nations procurement agencies
ActivShield technology is a portable, novel sterilization modality that does not require conventional infrastructure
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
This partnership will enable healthcare organizations to provide best-in-class patient/consumer experiences
Subscribe To Our Newsletter & Stay Updated